The latest price target for Moleculin Biotech (NASDAQ:MBRX) was reported by HC Wainwright & Co. on March 3, 2025. The analyst firm set a price target for $8.00 expecting MBRX to rise to within 12 months (a possible 614.29% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Moleculin Biotech (NASDAQ:MBRX) was provided by HC Wainwright & Co., and Moleculin Biotech maintained their buy rating.

There is no last upgrade for Moleculin Biotech

There is no last downgrade for Moleculin Biotech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moleculin Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moleculin Biotech was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.

While ratings are subjective and will change, the latest Moleculin Biotech (MBRX) rating was a maintained with a price target of $8.00 to $8.00. The current price Moleculin Biotech (MBRX) is trading at is $1.12, which is out of the analyst’s predicted range.